Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
243.25
+0.99 (+0.41%)
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
253,070
Open
241.70
Bid (Size)
235.23 (2)
Ask (Size)
251.27 (2)
Prev. Close
242.26
Today's Range
236.70 - 243.90
52wk Range
141.97 - 304.39
Shares Outstanding
118,847,693
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
How Is The Market Feeling About Alnylam Pharmaceuticals?
Today 8:45 EST
Via
Benzinga
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
December 09, 2024
Via
Benzinga
Performance
YTD
+24.79%
+24.79%
1 Month
-3.08%
-3.08%
3 Month
-10.24%
-10.24%
6 Month
+1.29%
+1.29%
1 Year
+27.22%
+27.22%
More News
Read More
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
November 25, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)
November 04, 2024
Via
Benzinga
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
October 31, 2024
Via
Benzinga
Why NASDAQ:ALNY qualifies as a high growth stock.
October 15, 2024
Via
Chartmill
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
November 17, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
November 12, 2024
Via
Benzinga
This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
November 12, 2024
Via
Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today
September 30, 2024
Via
Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
September 26, 2024
Via
Benzinga
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 04, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
October 31, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
October 30, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
October 23, 2024
Via
Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
October 18, 2024
Via
Investor's Business Daily
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
October 17, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
October 16, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
October 11, 2024
Via
Benzinga
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
October 09, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
October 06, 2024
Via
Benzinga
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
October 03, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
September 29, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.